- PRICING
- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
EN
因
INCY
因塞特医疗
121.07
-0.48-0.39%After Hours: 121.90 +0.83 +0.69%19:52 08/11 EDT
OPEN/PREV CLOSE121.13/121.55
TODAY RANGE120.06-122.28
VOL179
MARKET CAP24.54B
52 WEEK RANGE78.20-132.60
AVG VOL (3M)1.89M
% TURNOVER0.53%
TURNOVER0
P/E (TTM)15.43
% RANGE1.83%
EPS(TTM)7.85
P/E(FORWARD)58.07
P/B3.835
BVPS31.57
DIVIDEND--
P/S4.673
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP24.05B
SHARES OUTSTANDING202.70M
NEXT EARNINGS10/26-10/30
FREE FLOAT198.65M
LOT SIZE1
EX-DATE09/01/2000
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders
TipRanks·4d ago
Top Incyte Insiders Cash In On Major Stock Sale Moves
Simply Wall St·08/05 08:19
Incyte (INCY) Could Be 5% Overvalued Following Opzelura Approval And Higher Guidance
TipRanks·08/05 02:06
Top Incyte Insiders Quietly Cash In On Major Stock Sale
Benzinga·08/04 18:12
Mizuho Maintains Outperform on Incyte, Raises Price Target to $137
TipRanks·08/04 12:17
Incyte price target raised to $137 from $121 at Mizuho
TipRanks·08/03 15:36
Mizuho Securities Remains a Buy on Incyte (INCY)
Seeking Alpha·08/03 14:05
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Benzinga·08/03 12:16
Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Dow Jones·08/03 10:52
Incyte Is Maintained at Outperform by Leerink Partners
Dow Jones·08/03 10:52
Incyte Price Target Raised to $155.00/Share From $131.00 by Leerink Partners
Benzinga·08/03 10:42
Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155
Same Industry
Name/Symbol
Change%
Price